Pfizer and Celldex Therapeutics (CLDX) Present Data on CDX-110 at ASCO
More News related to CLDX
- Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
- Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
- Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
- Celldex Therapeutics (CLDX) Announces Positive Results From Phase Studies of CDX-1307
- Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
More News related to PFE
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
- Standpoint Raised Its FY10 Price Target on Pfizer (PFE) to $24
- Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
Pfizer (NYSE: PFE) and Celldex Therapeutics (NASDAQ: CLDX) announced the presentation of updated data from two clinical trials of CDX-110 in newly-diagnosed glioblastoma multiforme (GBM) at ASCO.
CDX-110, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII), was developed by Celldex Therapeutics and is now partnered with Pfizer.
John H. Sampson, MD, PhD, Associate Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center said, "Data from the 40 evaluable patients in ACTIVATE and ACT II continue to suggest that vaccination with CDX-110 may be able to improve time to tumor recurrence and overall survival when used in patients with newly-diagnosed GBM. These data also continue to suggest that tolerability and side effects associated with CDX-110 are minimal. These results are very encouraging and we look forward to the results from the ongoing multi-center ACT III Phase 2 study."
More from Release
Related Categories
FDAStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
